Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

On Sep. 25th, Upper Biotech applied for IPO was accepted by Shanghai Stock Exchange. At present, it has 7 listed enterprise on STAR Market, 2 registered upcoming companies and 5 waitings.

October 9, with the endorsement of Premier Li Keqiang, the State Council issued the Opinions on Further Improving the Quality of Listed Companies (hereinafter referred to as the Opinions).

From August to September 2020, the COVID-19 testing products of 5 companies around the world are included in the World Health Organization (WHO) Emergency Use Listing (the full English name is "Emergency Use Listing", "EUL" for short), of wh

From July to September, eight Chinese in vitro diagnostic companies have successively obtained Emergency Use Authorization(EUA) issued by US Food and Drug Administration (FDA) .

NGS cancer companion diagnostics is an emerging industry in China, and its industry concentration has gradually increased over the past 6 years around development.

The Supreme Law and the National Medical Insurance Bureau issued a document: From now on, medical commercial bribery cases will be notified to the Medical Insurance Bureau

Recently, Gofar issued a report (draft) on the acquisition of KOALSON, proposing to purchase the 99.9779% of KOALSON's shares held by eight people with the transaction price of about 356 million yuan by issuing shares and paying cash.

In Sep. 16th, Zhejiang Gongdong Medical Technology Co., Ltd. successfully listed on SSE (Shanghai Stock Exchange).

Recently, Gilead Sciences announced that it has reached a definitive agreement with the American biotechnology company Immunomedics (Nasdaq: IMMU).

Beijing Bohui Innovation Biotechnology acquires a total of 50% of ABIOQUANT BIO-MEDCAL TECHNOLOGY with RMB 24 million in cash.